» Articles » PMID: 30545255

In Vitro Removal of Anti-infective Agents by a Novel Cytokine Adsorbent System

Overview
Date 2018 Dec 15
PMID 30545255
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives:: The aim of this study is to describe the in vitro adsorption of anti-infective drugs onto an extracorporeal cytokine adsorber.

Methods:: Various anti-infective drugs (β-lactams, quinolones, aminoglycosides, glycopeptides, azole antimycotics) were prepared in normal saline 0.9% and human albumin 5%, and pumped through a cytokine cartridge (CytoSorb; CytoSorbents Corporation, Monmouth Junction, NJ, USA) at a flow rate of 1.2 L/h for 1.5 h. In addition, meropenem and ciprofloxacin were dissolved in reconstituted blood and run through a CytoSorb cartridge, which was integrated into a continuous renal replacement therapy circuit with a flow rate of 2 L/h for 18 h. Samples from the solution, pre- and post-filter, were quantified by high-performance liquid chromatography with ultraviolet detection and fluorescence polarisation immunoassay.

Results:: Observed mean clearance of the drugs in normal saline was 1.22 ± 0.07 L/h. In human albumin, clearance was 1.29 ± 0.08 L/h. In reconstituted blood, clearance of meropenem decreased from 5.4 to 1.4 L/h and for ciprofloxacin from 6.3 to 4.3 L/h within the first 1.5 h because of early drug adsorption. Continuous renal replacement therapy clearance measured without CytoSorb was stable at 2 and 1.7 L/h, respectively. Approximately 400 mg of meropenem and 300 mg of ciprofloxacin had been adsorbed by CytoSorb, suggesting that these amounts are the maximum adsorptive capacity for these drugs.

Conclusion:: In these settings, all tested drugs were adsorbed by the cartridge in relevant amounts. The identified maximum adsorptive capacity and the rapid decline in concentration during the first 1.5 h of CytoSorb use suggest that the administration of an additional dose within the first hours of CytoSorb treatment may be reasonable. In addition, early therapeutic drug monitoring should be considered.

Citing Articles

To Hemoadsorb or Not to Hemoadsorb-Do We Have the Answer Yet? An Updated Meta-Analysis on the Use of CytoSorb in Sepsis and Septic Shock.

Orban C, Bratu A, Agapie M, Borjog T, Jafal M, Sima R Biomedicines. 2025; 13(1).

PMID: 39857764 PMC: 11762373. DOI: 10.3390/biomedicines13010180.


Impact of hemoadsorption with CytoSorb® on meropenem and piperacillin exposure in critically ill patients in a post-CKRT setup: a single-center, retrospective data analysis.

Asgarpur G, Weber F, Kiessling P, Akbari N, Stroben F, Kleikamp B Intensive Care Med Exp. 2025; 13(1):7.

PMID: 39826040 PMC: 11741966. DOI: 10.1186/s40635-025-00716-0.


elimination of antimicrobials during ADVanced Organ Support hemodialysis.

Konig C, Frey O, Himmelein S, Mulack L, Brinkmann A, Perez Ruiz de Garibay A Front Pharmacol. 2024; 15:1447511.

PMID: 39737068 PMC: 11682888. DOI: 10.3389/fphar.2024.1447511.


REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial.

Hohn A, Malewicz-Oeck N, Buchwald D, Annecke T, Zahn P, Baumann A Crit Care. 2024; 28(1):406.

PMID: 39668341 PMC: 11639119. DOI: 10.1186/s13054-024-05175-9.


Myoglobin adsorption and saturation kinetics of the cytokine adsorber Cytosorb® in patients with severe rhabdomyolysis: a prospective trial.

Graf H, Grafe C, Bruegel M, Zoller M, Maciuga N, Frank S Ann Intensive Care. 2024; 14(1):96.

PMID: 38907120 PMC: 11192705. DOI: 10.1186/s13613-024-01334-x.